奧比中光(688322.SH):已將十餘款主流產品集成到英偉達Jetson平台
格隆匯12月9日丨奧比中光(688322.SH)在投資者互動平台表示,截至目前,公司已將十餘款主流產品集成到英偉達Jetson平台,包括Gemini330系列(結構光)、Femto系列(iToF)等。英偉達平台及生態的開發者/客户進行機器人等AI應用終端的仿真測試開發時,可以直接搭載適配奧比中光集成產品快速打造應用於移動感知、避障識別、體積測量、3D建模、體感交互等領域的視覺方案。公司與英偉達等海外合作伙伴保持良好的業務/生態合作關係,方便公司高效鏈接英偉達AI應用生態,更好地打造Orbbec×NVIDIA高性能3D視覺應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.